AIM ImmunoTech Future Growth
Future criteria checks 2/6
AIM ImmunoTech's earnings are forecast to decline at 0.3% per annum while its annual revenue is expected to grow at 74.5% per year. EPS is expected to grow by 8.1% per annum.
Key information
-0.3%
Earnings growth rate
8.1%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 74.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8 | -32 | N/A | N/A | 1 |
| 12/31/2025 | 3 | -24 | N/A | -6 | 2 |
| 12/31/2024 | 0 | -20 | N/A | -8 | 2 |
| 9/30/2024 | 0 | -24 | -21 | -21 | N/A |
| 6/30/2024 | 0 | -28 | -24 | -23 | N/A |
| 3/31/2024 | 0 | -31 | -23 | -22 | N/A |
| 12/31/2023 | 0 | -29 | -22 | -21 | N/A |
| 9/30/2023 | 0 | -21 | -18 | -18 | N/A |
| 6/30/2023 | 0 | -19 | -17 | -17 | N/A |
| 3/31/2023 | 0 | -19 | -17 | -17 | N/A |
| 12/31/2022 | 0 | -19 | -16 | -16 | N/A |
| 9/30/2022 | 0 | -21 | -16 | -16 | N/A |
| 6/30/2022 | 0 | -18 | -15 | -14 | N/A |
| 3/31/2022 | 0 | -19 | -14 | -14 | N/A |
| 12/31/2021 | 0 | -19 | -15 | -14 | N/A |
| 9/30/2021 | 0 | -17 | -12 | -11 | N/A |
| 6/30/2021 | 0 | -17 | -11 | -11 | N/A |
| 3/31/2021 | 0 | -14 | -11 | -10 | N/A |
| 12/31/2020 | 0 | -14 | -11 | -10 | N/A |
| 9/30/2020 | 0 | -12 | -10 | -10 | N/A |
| 6/30/2020 | 0 | -11 | -10 | -9 | N/A |
| 3/31/2020 | 0 | -10 | -11 | -11 | N/A |
| 12/31/2019 | 0 | -9 | -9 | -9 | N/A |
| 9/30/2019 | 0 | -10 | -9 | -9 | N/A |
| 6/30/2019 | 0 | -10 | -10 | -10 | N/A |
| 3/31/2019 | 0 | -10 | -10 | -10 | N/A |
| 12/31/2018 | 0 | -10 | -11 | -11 | N/A |
| 9/30/2018 | 0 | -10 | -9 | -9 | N/A |
| 6/30/2018 | 0 | -8 | N/A | -8 | N/A |
| 3/31/2018 | 0 | -8 | N/A | -7 | N/A |
| 12/31/2017 | 0 | -8 | N/A | -8 | N/A |
| 9/30/2017 | 0 | -7 | N/A | -9 | N/A |
| 6/30/2017 | 0 | -9 | N/A | -10 | N/A |
| 3/31/2017 | 0 | -8 | N/A | -9 | N/A |
| 12/31/2016 | 0 | -8 | N/A | -7 | N/A |
| 9/30/2016 | 0 | -9 | N/A | -9 | N/A |
| 6/30/2016 | 0 | -10 | N/A | -9 | N/A |
| 3/31/2016 | 0 | -14 | N/A | -13 | N/A |
| 12/31/2015 | 0 | -15 | N/A | -16 | N/A |
| 9/30/2015 | 0 | -17 | N/A | -17 | N/A |
| 6/30/2015 | 0 | -17 | N/A | -17 | N/A |
| 3/31/2015 | 0 | -17 | N/A | -15 | N/A |
| 12/31/2014 | 0 | -17 | N/A | -14 | N/A |
| 9/30/2014 | 0 | -16 | N/A | -13 | N/A |
| 6/30/2014 | 0 | -17 | N/A | -13 | N/A |
| 3/31/2014 | 0 | -16 | N/A | -14 | N/A |
| 12/31/2013 | 0 | -16 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HXB2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HXB2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HXB2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HXB2's revenue (74.5% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: HXB2's revenue (74.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HXB2's Return on Equity is forecast to be high in 3 years time